Huntington's treatment quest reaches first pluripotent stem cell trial, with safety now under review

An update connected the archetypal objective proceedings evaluating a pluripotent stem cell-derived neural stem compartment therapy for Huntington's illness was presented astatine the ISSCR 2026 Annual Meeting. The Phase Ib/IIa REGEN4HD survey represents a important translational milestone pursuing years of preclinical research, pivotal information studies, regulatory engagement and objective proceedings development.